Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/8073
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRawaa Ali Hussein, Mushtak T. S. Al-Ouqaili-
dc.contributor.authorYasin H. Majeed-
dc.date.accessioned2022-11-03T20:37:04Z-
dc.date.available2022-11-03T20:37:04Z-
dc.date.issued2021-09-
dc.identifier.issn1319562X-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/8073-
dc.description.abstractBackground and objectives: Peptic ulcer disease, chronic gastritis, and stomach cancer are all caused by H. pylori. The most notable drug for the treatment is the antibiotic clarithromycin, which is currently the drug of choice. H. pylori clarithromycin resistance has been associated with point mutations in 23srRNA, the most prominent of which are A2143 and A2144G. In H. pylori bacteria, methylase synthesis, macrolide-inactivating enzyme activity, and active efflux have all been found to be resistance mechanisms. The goal of the study is to determine how resistant H. pylori is to clarithromycin and what the minimum inhibitory concentration is for various antimicrobials. Furthermore, gastro-endoscopy will be performed on Iraqi patients to detect the presence of A2143G and A2144G point mutations in Helicobacter pylori infections, as diagnosed from the pyloric region and other anatomical regions. Methods: One hundred fifteen samples were collected from patients strongly suspected of H. pylori infection presented for upper gastrointestinal endoscopy at Ramadi Teaching Hospitals and Private Clinics for the period from January 2020 until February 2021. Specimens were cultured on brain heart infusion agar containing various antibiotics and were incubated at 37 C under microaerophilic conditions. For identification of H. pylori, isolates of the biochemical tests and RT-PCR assay were applied. The Epsilometer test was used in the antibiotic susceptibility testing as dependent on the CLSI standard. The Restriction Fragment Length Polymorphism technique was used to determine point mutations. Results: In total, 55 (47.8%) Helicobacter pylori isolates were cultured from the 115 biopsy specimens, among which 16 (29.1%), 38 (69.1%), 20 (36.4%), and 40 (72.7%) revealed some degree of resistance to levofloxacin, clarithromycin, ciprofloxacin, and metronidazole, respectively. The frequency of A2144G and A2143 point mutations were 23 (60.5%) and 19 (50%), respectively. Conclusions: According to our results, Helicobacter pylori showed high resistance to clarithromycin. Our results demonstrate the requirement for antibiotic susceptibility testing and molecular methods in selecting drug regimens.en_US
dc.language.isoenen_US
dc.publisherSaudi Journal of Biological Sciences (by Elsevier B.V. on behalf of King Saud University)en_US
dc.subjectHelicobacter pylorien_US
dc.subjectClarithromycinen_US
dc.subjectPCR-RFLPen_US
dc.subjectPoint Mutationen_US
dc.titleDetection of clarithromycin resistance and 23SrRNA point mutations in clinical isolates of Helicobacter pylori isolates: Phenotypic and molecular methods.en_US
dc.typeArticleen_US
Appears in Collections:كلية الصيدلة

Files in This Item:
File Description SizeFormat 
2.pdf1.3 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.